Eli Lilly and Co. (LLY) said Monday its experimental type-2 diabetes drug dulaglutide met its primary endpoint of lowering blood sugar levels compared with three standard therapies.
Eli Lilly said it plans to submit dulaglutide to U.S. regulatory authorities in 2013, subject to meeting requirements for assessment of cardiovascular risk.
Dulaglutide is an long-acting glucagon-like peptide 1 analog being studied as a once-weekly treatment for type 2 diabetes.
In the trials, primary efficacy endpoints, as measured by reduction in hemoglobin A1c (HbA1c) at the 1.5 mg dose, were met in three studies.
Dulaglutide reduced HbA1c levels more than twice-daily injections of Bristol-Myers Squibb Co.'s (BMY) Byetta administered for six months, oral metformin given for 26 weeks and Merck & Co. Inc.'s (MRK) once-daily oral Januvia for one year.
The most common side effects for dulaglutide were gastrointestinal-related. The adverse event findings are consistent with prior studies of dulaglutide.
Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin. About 25.8 million Americans and an estimated 366 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.
Shares of Eli Lilly are trading at $52.08, down 1.48%, on a volume of 6.4 million shares on the NYSE.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.